Nonopioid therapy is an important tool for the treatment of chronic pain. But agents differ as to efficacy and safety in older patients. This program reviews the different classes of nonopioid medications, their efficacy in different types of pain, and their use in older patients. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

Treating chronic pain in older individuals and balancing analgesia and adverse effects in this population, which is often afflicted with multiple comorbidities, is challenging. This program reviews the assessment and nonpharmacologic treatment of chronic pain in patients aged 65 years and older. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used for pain management in a variety of settings and for a variety of conditions. This podcast summarizes the evidence for efficacy as well as for toxicities associated with this drug class and outlines current guideline recommendations. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).

This activity will discuss the epidemiology and pathophysiology of acute and chronic pain, patient assessment, assessment of risk for opioid-related aberrant behaviors, nonpharmacologic approaches to pain management, and non-opioid analgesics. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 3/19/2020 and they are subject to change as new information is published.

This activity will review the general principles of opioid prescribing, key concepts including misuse, abuse, tolerance, physical dependence, opioid use disorder, adverse effects and metabolism of opioids, and instructions for safe storage and disposal. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 3/19/2020 and they are subject to change as new information is published.

This activity will discuss initiating opioids in acute and chronic pain, long term management of patients on opioid therapy, patient counseling, and fundamentals of addiction medicine. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 3/19/2020 and they are subject to change as new information is published.

The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain versus the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse to manage patients’ pain and medication use optimally. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA).